Compare DNUT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DNUT | LXEO |
|---|---|---|
| Founded | 1937 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.4M | 731.3M |
| IPO Year | 2021 | 2023 |
| Metric | DNUT | LXEO |
|---|---|---|
| Price | $3.65 | $7.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $6.22 | ★ $18.60 |
| AVG Volume (30 Days) | ★ 2.4M | 1.8M |
| Earning Date | 02-24-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,534,272,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.19 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.50 | $1.45 |
| 52 Week High | $9.56 | $10.99 |
| Indicator | DNUT | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 34.87 | 35.65 |
| Support Level | $4.12 | $6.90 |
| Resistance Level | $4.49 | $10.75 |
| Average True Range (ATR) | 0.22 | 0.85 |
| MACD | -0.07 | -0.32 |
| Stochastic Oscillator | 3.30 | 12.73 |
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.